Generation in Human Plasma of Misfolded, Aggregation-Prone Electronegative Low Density Lipoprotein  by Greco, Giulia et al.
628 Biophysical Journal Volume 97 July 2009 628–635Generation in Human Plasma of Misfolded, Aggregation-Prone
Electronegative Low Density Lipoprotein
Giulia Greco,† Gabor Balogh,‡ Roberto Brunelli,§ Graziella Costa,† Marco De Spirito,{ Laura Lenzi,†
Giampiero Mei,k Fulvio Ursini,†† and Tiziana Parasassi†*
†Istituto di Neurobiologia e Medicina Molecolare, CNR, Rome, Italy; ‡Institute of Biochemistry, Biological Research Center, Hungarian Academy
of Sciences, Szeged, Hungary; §Dipartimento di Ostetricia e Ginecologia, Universita` di Roma ‘‘La Sapienza’’, Rome, Italy; {Istituto di Fisica,
Facolta` di Medicina e Chirurgia, Universita` Cattolica del Sacro Cuore, Rome, Italy; kDipartimento di Medicina Sperimentale e Scienze
Biochimiche, Universita` di Roma ‘‘Tor Vergata’’, Rome, Italy; and ††Dipartimento di Chimica Biologica, Universita` di Padova, Padua, Italy
ABSTRACT Human plasma contains small amounts of a low density lipoprotein in which apoprotein is misfolded. Originally
identiﬁed and isolated by means of anion-exchange chromatography, this component was subsequently described as electro-
negative low density lipoprotein (LDL)(), with increased concentrations associated with elevated cardiovascular disease
risk. It has been recognized recently as the trigger of LDL amyloidogenesis, which produces aggregates similar to subendothelial
droplets observed in vivo in early atherogenesis. Although LDL() has been produced in vitro through various manipulations, the
mechanisms involved in its generation in vivo remain obscure. By using a more physiological model, we demonstrate sponta-
neous, sustained and noticeable production of LDL() during incubation of unprocessed human plasma at 37C. In addition
to a higher fraction of amyloidogenic LDL(), LDL puriﬁed from incubated plasma contains an increased level of lysophospho-
lipids and free fatty acids; analysis of LDL lipids packing shows their loosening. As a result, during plasma incubation, lipid desta-
bilization and protein misfolding take place, and aggregation-prone particles are generated. All these phenomena can be
prevented by inhibiting calcium-dependent secretory phospholipases A2. Our plasma incubation model, without removal of
reaction products, effectively shows a lipid-protein interplay in LDL, where lipid destabilization after lipolysis threatens the
apoprotein’s structure, which misfolds and becomes aggregation-prone.INTRODUCTION
Subendothelial retention of low density lipoproteins (LDL),
mainly in the form of lipid droplets, activates a series of
biological events culminating in an inflammatory response,
which is considered the first hallmark of atherogenesis (1).
A high level of LDL in plasma is widely regarded as a major
risk factor for developing vascular disease, and can reason-
ably be assumed to be responsible for the accumulation of
lipids in the subendothelial space. However, a mechanistic
link between LDL levels and atherogenesis remains lacking,
and this gap in our knowledge has inspired the search for a
modification that transforms an otherwise innocuous choles-
terol carrier—the native LDL—into a new species able to
trigger an inflammatory response. To produce an LDL toxic
to arterial walls and able to reproduce early biological
disease events, several modifications have been attempted
in vitro, the most popular of which was massive lipid perox-
idation (2,3). Such drastic modifications in LDL elicit
inflammatory and unspecific toxic responses in cells in
culture, and result frequently in the production of aggregates
that are taken up by macrophages, thereby mimicking the
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. Open access under CC BY-NC-ND license.early formation of foam cells. A major limitation of the
oxidative theory of atherogenesis is the difficulty encoun-
tered in unequivocally detecting oxidatively modified LDL
in the bloodstream (4,5); this drawback prompted the search
for alternative, nonoxidative modifications.
Modified LDL that is toxic to cultured endothelial cells,
and that induces events compatible with a cell response-to-
injury has, in fact, been identified in human plasma (6).
This form of LDL was isolated by means of anion-exchange
chromatography, and subsequently named electronegative
LDL (LDL()). Many reports have described the relation-
ship between an increase in LDL() and increased cardio-
vascular disease risk. Indeed, several risk markers correlate
with LDL() levels, namely hypercholesterolemia, diabetes
mellitus types 1 and 2, kidney failure, exhausting physical
exercise, and postprandial lipemia (7–12). Finally, it has
been found that LDL() lipids are oxidized more readily
in vitro (13) and, significantly, that its apoprotein is mis-
folded, displaying structural and conformational modifica-
tions (14).
In the course of our effort to determine further character-
istics of this intriguing LDL(), we recently obtained clear
evidence that it is capable of promoting LDL amyloidogen-
esis (15). The misfolded character of apoB-100 in LDL(),
where the content of the b-sheet structure increases, repre-
sents the driving force behind LDL aggregation, whereas
the protein misfolding in native LDL is propagated through
a paradigmatic domino process. Consistent with protein
amyloidogenesis in general, a chaperon protein actually
doi: 10.1016/j.bpj.2009.05.005
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boosted in the presence of the b-sheet-rich amyloid b peptide.
Results obtained from a computational analysis of the apoB
structure confirms the ease with which these changes take
place by identifying a few peculiar loops that are extremely
prone to an a-to-b shift. On the other hand, the relevance of
the role played by oxidation in promoting LDL aggregation
was ruled out by the analysis of initial clusters (16). Indeed,
in LDL aggregates the individuality of initial LDL particles
is preserved, whereas oxidatively-modified LDL fuses.
Finally, in LDL fibrillogenesis, intermediate aggregates are
impressively similar to subendothelial droplets observed in
early atherogenesis (15).
Modified LDL with increased affinity for proteoglycans
was produced in vitro by secretory phospholipase A2 (17).
LDL() can also be produced, in vitro, from native LDL
(nLDL) by incubation in the presence of vascular cells
(18,19), or cobra venom phospholipase A2 (20). However,
the mechanism/s responsible for in vivo generation of
LDL() is/are still unknown.
We have already reported that LDL isolated from plasma
that was previously incubated overnight at 37C is prone to
amyloidogenic aggregation (16). In this study, we set out to
clarify some of the processes able to generate this aggrega-
tion-prone LDL in plasma.
MATERIALS AND METHODS
LDL isolation
LDLwas isolated fromvenous blood following routine procedures (16), either
from freshly collected plasma (LDL-F), or from plasma that had been incu-
bated previously at 37C for different durations (LDL-I). In some of the
experiments, LDL was isolated from serum. When specified, 0.1 mM of the
inhibitor of the family secretory-PLA2s, 4-bromophenacyl bromide (21,22)
(Sigma-Aldrich, Milan, Italy), or alternatively that of the calcium-dependent
lipoprotein-associated PLA2 (Lp-PLA2), Pefabloc (23,24) (Sigma-Aldrich),
was added to plasmaor serumat the beginning of incubation. The use of serum
instead of plasmawas a test for the chelating efficiency of the small amount of
EDTApresent in theVacutainer tubes used to collect blood, particularly when
activity of the calcium-dependent or independent PLA2had to be tested. From
our results (not shown), this EDTA amount did not exert any role on PLA2s
activities. Blood donors were healthy, normolipemic, and normal fasting
volunteers in the age range from 29 to 55 years. LDL concentrationwas deter-
mined as the apoprotein concentration by using the Bradford reagent. In total
LDL, subclasses were analyzed by using anion-exchange chromatography in
an A¨KTA-FPLC system (GE Healthcare, Amersham Biosciences, Piscat-
away, NJ) using a MonoQ 5/50 GL column and a multistep gradient from
0 to 0.3MNaCl. Percent amount of subclasseswas calculated from the elution
profiles by integrating the absorbance of each eluted peak using the Origin
software (Microcal Software, Northampton, MA).
Lipid analysis
Lipids were extracted from LDL by adding 3 mL of CHCl3/MeOH ¼ 1:2 to
0.8 mL of LDL samples. After vortexing, 0.8 mL of a 0.88% KCl solution,
plus 3 mL of CHCl3 were added, the samples were vortexed again, centri-
fuged, and the upper aqueous phase removed and discarded. The organic
phase was dried under a gentle stream of nitrogen and redissolved in
0.5 ml of CHCl3/MeOH ¼ 1:1; samples were stored at 20C until under-going analysis. All solvents contained 10 mg/L of butylated hydroxytoluene.
TLC analysis was carried out on silica gel TLC plates (Merck Kieselgel 60,
Merck, Darmstadt, Germany). Lipid classes were separated in chloroform/
methanol/30% ammonia (65:25:5 v/v). After elution, the lipids were exam-
ined and identified using authentic standards. The spots were scraped and
methylated in 2 mL of 5% acetyl chloride (in MeOH) at 80C for 2 h in
the presence of 15:0 FA internal standard. The resulting fatty acid methyl
esters were injected into a GC-MS system (GC-2010, Shimadzu Deutsch-
land GmbH, Duisburg, Germany) fitted with a BPX70 capillary column
(MS Wil GmbH, Wil, Switzerland).
Fluorescence measurements
LDL samples (50 mg of protein/ml) were equilibrated at 37C in the fluorim-
eter cell holder and blank spectra were acquired for subtraction later on. The
LDL was then labeled with 2-dimethylamino-6-lauroylnaphthalene (Laur-
dan, Molecular Probes, Eugene, OR) by adding 0.3 mL of a 1.3 mM solution
of the probe in dimethylsulfoxide, incubated for 15 min. After this, emission
spectra were acquired from 430 nm to 500 nm, using 360 nm excitation and
8 nm bandwidths. A GREG 200 fluorometer (ISS, Champaign, IL) fitted
with a xenon arc lamp and photon counting electronics (PX01; ISS) was
used. The cell holder was thermostatically maintained at 37.05 0.1C using
a circulating water bath. After subtraction of the blank, the Laurdan gener-
alized polarization (GP) value was calculated from the emission spectra
according to
GP ¼ ðI440  I490Þ=ðI440 þ I490Þ; (1)
where I440 and I490 are the emission intensities at 440 nm and 490 nm,
respectively (25).
Circular dichroism
Spectra from the different LDL samples (with apoprotein concentrations of
0.1 mM) were recorded on a JASCO spectropolarimeter (Tokyo, Japan)
using a 0.1 cm quartz cuvette. The cell holder compartment was maintained
at 375 0.1C. Six spectra were averaged for each measurement.
Light scattering
The light scattered from 1 mg/mL of LDL protein was monitored using
a commercial light scattering ALV spectrometer set-up (ALV, Langen,
Germany), consisting of a CGS-5000 rotating arm goniometer, a photomul-
tiplier tube (PMT) (EMI, Ruislip, UK), an ALV 5000 multi-tau digital corre-
lator operating at a sampling time of 200 ns, and an Innova 70 argon ion laser
(Coherent, Santa Clara, CA) operating at 488 nm and 100 mW. The scat-
tering cell was immersed in a refractive index matching fluid (toluene)
kept at 37 5 0.1C. Light scattering data were collected simultaneously
from a scattering volume of ~100 mm3, and analyzed using specially devel-
oped software. Angular runs were carried out with angles logarithmically
scaled in sin(q), where q is the scattering angle, ranging from 30 to 150.
RESULTS
LDL() is produced in plasma
LDL isolated from LDL-F is composed of a main fraction,
called nLDL, and of a minor, more electronegative fraction,
known as LDL(), which accounts for <10% of total LDL
(Fig. 1 A, solid curve) (6). When averaged over the 30
healthy individuals used in this study, LDL() levels
measured 8.2 5 0.5%. This fraction dramatically increased
when LDL was isolated from plasma – or serum – that had
been previously incubated at 37C (LDL-I) for ~20 h, inBiophysical Journal 97(2) 628–635
630 Greco et al.FIGURE 1 Conversion of nLDL in LDL() during plasma incubation.
(A) Representative FPLC chromatograms of LDL-F (solid curve) and
LDL-I after an incubation of 20 h (dashed curve) is reported. (B) PercentBiophysical Journal 97(2) 628–635parallel with a decrease in nLDL (Fig. 1 B, dotted curve).
Averaged over all subjects, the amount of nLDL decreased
to 42.1 5 2.5%, with a corresponding increase in LDL()
to 57.9 5 1.6%. This increase in LDL() was not affected
by the addition of antioxidants to plasma, such as 0.1 mM
Trolox C or 0.1–0.3 mM vitamin C (not shown), thus ruling
out any involvement of oxidative mechanisms. No LDL()
formation was observed when plasma was incubated at 4C
or, as reported (14), when LDL purified from fresh plasma
was subsequently incubated at 37C.
The time-course of the process (Fig. 1 B) suggests a direct
and quantitative conversion of nLDL into LDL(), con-
firmed by the linear plot of nLDL versus LDL() percent-
ages (Fig. 1 C).
Identiﬁcation of the enzymatic activity that primes
LDL() formation
Based on previous in vitro evidence (20), the most likely
candidate enzyme responsible for the formation of LDL()
was a phospholipase A2 present in plasma. In fact, present
evidences show that with respect to LDL-F, both lysophos-
phatidylcholine (LPC) and free fatty acid (FFA) content
increased in LDL-I (Fig. 2 A), consistent with the LPC/PC
ratio (Fig. 2 B) calculated from GC-MS analysis. No relevant
changes were observed in sphingomyelin, cholesterol esters
or triglycerides (not shown). Various PLA2s are present in
plasma: the family of the 10 secretory, calcium-dependent
PLA2s (sPLA2s), and the calcium-independent PLA2, also
known as Lp-PLA2, or platelet-activating factor acetylhy-
drolase. The effect that these enzymes exert in the formation
of LDL() in plasma—or in serum, as detailed in Materials
and Methods—was tested by using specific inhibitors. The
results, reported in Fig. 2 C, unequivocally show that only
the inhibitor of sPLA2s hinders LDL() formation, and
prevents the production of LPC and FFA (Fig. 2, A and B).
On the other hand, the involvement of Lp-PLA2 in the
conversion process can be ruled out on account of the
absence of any effect exerted by its specific inhibitor.
Effect of phospholipid hydrolysis on LDL lipid
structure
The observed increase in LPC—and in FFA—is expected to
modify the packing of surface lipids in LDL. To verify and
characterize this anticipated modification we used the spec-
tral sensitivity of the lipophilic fluorescent probe Laurdan,
widely used as a sensitive detector of changes in lipid
dynamics (25,26). We acquired Laurdan spectra and calcu-
lated the GP value (Eq. 1) in LDL purified after different
plasma incubation times. A progressive spectral shift toward
amount of nLDL (-, solid curve) and of LDL() (d, dashed curve) versus
plasma incubation time. Average values of three independent readings, with
SE. (C) Percent amount of nLDL versus LDL(). The solid line represents
a linear fit. Slope ¼ 1.
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(A) Representative chromatogram of lipid extracted from LDL-F and from
LDL-I purified after 20 h of plasma incubation, also in the presence of the
sPLA2 or LpPLA2 inhibitor. LPC, lysophosphatidylcholine; SM, sphingo-
myelin; PC, phosphatidylcholine; FFA, free fatty acids. (B) LPC/PC ratio
calculated in the same samples as in A, determined by GC-MS. Average
with SE calculated from three independent experiments; *significance
p% 0.05. (C) Percentage of nLDL (white) and LDL() (gray) subfractions
in total LDL determined in the above-mentioned samples. Averages of:
*, 23; **, 31; and ***, three independent experiments, with SE.longer wavelengths was observed with increased plasma
incubation times (Fig. 3 A), resulting in progressively lower
GP values (Fig. 3 B). As has been reported previously (25),
this is related to an increased water penetration into lipids,
caused by a loosening of their packing. The kinetics of GP
decrease was consistent with the increase in LDL() content
(Fig. 3 B). In agreement with the variation in the production
of LPC (Fig. 2), in the presence of the sPLA2s inhibitor no
significant GP modification was observed, whereas a GP
decrease still occurred when using the LpPLA2 inhibitor
(Fig. 3 C).
Effect of plasma incubation on LDL apoprotein
misfolding and on aggregation
In agreement with its higher content in LDL(), a decreased
ellipticity was observed in LDL-I, isolated after a plasma
incubation time of 20 h, as compared to that seen in LDL-
F (Fig. 4 A) (14). Due to the presence of a consistent fraction
of nLDL in LDL-I (Fig. 1 B), its CD absorbance was still
higher than that of isolated LDL(). The consequences of
the presence of PLA2 inhibitors during plasma incubation
could also be detected through the CD absorbance spectra.
Inhibition of the sPLA2s prevented the ellipticity loss, result-
ing in a CD spectrum that overlapped the LDL-F’s corre-
sponding spectrum. Inhibition of Lp-PLA2, on the other
hand, had no effect (Fig. 4 A).
Light scattering intensity results showed that isolated
LDL-I further incubated at 37C forms aggregates, whereas
LDL-F does not (Fig. 4 B) (14). In a previous study, we
showed that the trigger for LDL aggregation resides in the
misfolded apoB-100 present in LDL() (15). Hence, the
final problem we sought to resolve regarded the effects of
phospholipase inhibition on LDL aggregation. Inhibitors
were added to plasma during incubation; we then monitored
the light scattering intensity versus time on isolated LDL
samples. In agreement with the lack of an increase in
LDL() and of a structural modification in its apoprotein,
LDL-I isolated from plasma in which the sPLA2s inhibitor
was present did not show any aggregation. Conversely, inhi-
bition of Lp-PLA2 in plasma had no effect, and LDL-I
aggregated in a way similar to that seen in the sample
without an added inhibitor (Fig. 4 B).
These findings also confirm that LDL() produced by
sPLA2s activity in plasma is in all respects identical to the
LDL() isolated in small amounts from fresh plasma.
DISCUSSION
Almost 30 years after the groundbreaking identification of
the electronegative LDL subfraction (6), LDL(), which
lately has been associated with several markers of cardiovas-
cular disease risk (7–12), in our quest for the mechanism
responsible for LDL() generation in vivo we have suc-
ceeded in obtaining evidence for a spontaneous lipolyticBiophysical Journal 97(2) 628–635
632 Greco et al.FIGURE 3 Loosening of LDL lipid structure after phospholipid hydro-
lysis. (A) Representative normalized Laurdan fluorescence emission spectra
measured in LDL purified from plasma after various incubation times: 0, 2,
4, and 20 h. (B) Average GP values of similar samples, as a function of
plasma incubation time, from three independent experiments with SE
(-). For comparison, the FPLC data on the percentage amount of
LDL() are reproduced (d). (C) Laurdan GP values measured in LDL-F,
in LDL-I isolated after 4 h of plasma incubation, and after the same length
of time with incubation carried out in the presence of the sPLA2s, or of the
LpPLA2 inhibitor. Average of three independent experiments with SE.Biophysical Journal 97(2) 628–635conversion of nLDL into LDL() in human plasma. We
have demonstrated this process by means of the simple incu-
bation of plasma at 37C, resulting in the generation of
LDL() that has all the features of a misfolded protein prone
to amyloid aggregation, commensurate with those described
previously for LDL() isolated from fresh plasma (14–16).
In our ex vivo conditions, this prompt and massive produc-
tion of LDL() is a nonequilibrium process, in the absence
of the organism’s removal mechanisms. Our procedure
also excludes the possibility that LDL() undergoes a lipo-
lytic modification in the artery wall—either intracellular or
extracellular—and then returns to the plasma compartment;
an unsolved problem concerning instead the small quantity
of circulating oxidized LDL (4).
The report that, in vitro, cobra venom PLA2 efficiently
promotes the formation of LDL() from nLDL (20),
FIGURE 4 Ellipticity loss of LDL apoprotein and LDL aggregation after
phospholipid hydrolysis. (A) CD spectra, and (B) light scattering intensity
curves obtained from: LDL-F (-), LDL-I isolated after 20 h of plasma incu-
bation (d), also in the presence of sPLA2s (:) or of Lp-PLA2 inhibitor
(A). In A, the CD spectrum of LDL() (solid curve, no symbol), isolated
and collected by means of anion exchange chromatography, is also reported.
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in vivo. Our model of unprocessed plasma incubation shows
unequivocally that hydrolysis of PC in LDL can occur in
plasma and is accompanied by LDL() formation. The
temperature dependence of this process is a major argument
in favor of an enzymatic reaction: no increase in LDL()
could be detected when plasma was incubated at 4C.
Among lipolytic enzymes involved in intravascular LDL
remodeling, particular attention has been paid recently to
some of the 10 components of the family of secretory,
calcium-dependent PLA2s (sPLA2s), and to the lipoprotein
associated, calcium-independent PLA2 (Lp-PLA2 or
platelet-activating factor acetylhydrolase) (17,27–29). LDL
treated in vitro with these enzymes has not been structurally
characterized in the past, but has been shown to elicit cellular
responses that mimic the early phases of atherogenesis, and
to enhance the binding of lipoproteins to proteoglycans.
Type II, V, and X sPLA2 have been suggested to play
a role in cardiovascular diseases. Data from a study concern-
ing the Type II suggest the presence of this phospholipase
both in control and in stable/unstable angina patients (30).
Data on the Type X indicate that expression of this sPLA2
is constitutive rather that inducible (27) and that it has a
potent lipolytic effect on LDL, with consequences on an
increased negative charge (31). Although several studies
exist on the quantitative evaluation of other sPLA2 classes
in the vascular tissue or in the atherosclerotic lesions, little
is reported on specific activity measurement in plasma.
Significantly, the products of their activity are proinflamma-
tory lipids such as lysophospholipids and free unsaturated
fatty acids. Clinical observations also strongly support an
association between high levels of circulating sPLA2s and
increased risk of cardiovascular disease (17,32,33), thus
highlighting two possible sites where these enzymes act: in
the subendothelium, or alternatively on circulating lipopro-
teins.
Without excluding other possible mechanisms for LDL
modification that take place in the subendothelium, our
data in this study shows that, in plasma, phospholipase
activity on circulating LDL results in an increased concentra-
tion of lysophospholipids. The straightforward effect of a
sPLA2s inhibitor strongly supports the involvement of one
or more members of this family of enzymes. Instead, Lp-
PLA2 is apparently ruled out by the absence of any effect
of its specific inhibitor. This lipoprotein-associated phospho-
lipase would also be expected to generate LDL() during the
incubation of isolated LDL, an effect that, consistent with
our previous data (15,16), was not in fact observed. Indeed,
no LDL() generation was observed incubating at 37C
LDL after its isolation.
Laurdan GP served well for the detection of changes
induced on LDL lipids by an increased LPC content. LPCs
possess a structure similar to that of most detergents and
therefore exert a loosening effect on the packing of LDL
surface lipids. Laurdan GP value showed quite a significantdiminution, from 0.53 to 0.34. Although this occurrence
cannot be translated into a quantitative evaluation of lipid
compositional change, it serves to provide an idea of the
structural effect when compared with what observed in
membranes containing cholesterol. In phospholipid vesicles
containing 30% cholesterol—a concentration close to that
present in cell plasma membranes—such a GP decrease
occurs with a temperature increase of >15C (25).
LDL() signature chiefly consists in a misfolding of apoB-
100, with an a-to-b structural shift. Given that apoB-100 is
a multipotential protein that interacts closely with lipids,
and possesses several functional regions that can all respond
to key modifications in selected domains (34–36), it is not
surprising that significant lipid loosening is able to affect
apoB-100 conformation.
An interesting question concerns the relationship between
phospholipid hydrolysis and protein misfolding. Following a
consensus model for LDL structure (37), the apoB-100 is
located in the outer surface together with phospholipid polar
heads, but at the same time seeps through the interfacial layer
and down to the core. In this situation, conformational modi-
fications in the protein have already been reported as a conse-
quence of lipid modification (for a comprehensive review see
Hevonoja et al. (36)). Worthy of note, a treatment that uses
bee venom PLA2 has been reported to alter the immunoreac-
tivity of a protein site (38). A further example of this inter-
play between protein and lipid structure is provided by our
previous demonstration that the binding to the protein of
a single estradiol molecule per LDL particle is able to affect
the structure of both the protein and the lipid’s interfacial and
core regions (39). We can therefore conclude that phospho-
lipid hydrolysis/structural loosening, on one hand, and the
apoprotein misfolding, on the other hand, represent an addi-
tional clear example of the tight lipid-protein structural inter-
action in this complex and relevant particle. In addition, our
results propose a mechanism for the a-to-b switch in the
apoB-100 few loops, identified previously through computa-
tional analysis as extremely aggregation-prone (15).
The LDL() produced on a massive scale in incubated
plasma is in all respects identical to LDL() present in small
amounts in fresh plasma, the amyloidogenic character of its
protein included. The possibility that aggregation might be
primed directly by LPC rather than by misfolded apoB-100
is extremely unlikely. Although LPCs possess structural
characteristics similar to those of detergents and can there-
fore promote fusion, LDL aggregates do not contain fused
LDL. We have shown previously the presence, in LDL clus-
ters, of readily identifiable particles of the initial LDL size.
Fractal analysis and the determination of a reaction-limited
interaction mechanism both suggested a few protein sites
as the drivers that produce aggregation (16).
Subsequent to our previous report on the aggregation
propensity of LDL isolated from plasma that was previously
incubated overnight at 37C (16), we now identified in
LDL() the modified particle that is produced in plasma,Biophysical Journal 97(2) 628–635
634 Greco et al.able to trigger the amyloidogenic process, and a mechanism
for its generation.
Although the possibility that other mechanisms capable of
affecting the lipids or protein structure in LDL exists, the
picture emerging from this evidence involves an active lipo-
lytic process occurring in plasma that is able to destabilize
the structure of LDL lipids. Concurrently, a misfolding in
apoB-100 takes place, which renders the LDL particle aggre-
gation-prone by means of a process that has already been
described as typically amyloidogenic. Intriguing questions
that remain open concern the regulation of sPLA2s concen-
tration and/or activity in vivo, together with the metabolic
processes able to remove the apparently continuously formed
LDL(). Answer to these questions will add to the role of
LDL() in vascular disease and possibly to pharmaceutical
interventions for regulating its concentration.
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